ZA94887B - A combination of neurotrophin and antibody directed toward myelinassociated neurite growth inhibitory protein promotes central nervous system regeneration - Google Patents

A combination of neurotrophin and antibody directed toward myelinassociated neurite growth inhibitory protein promotes central nervous system regeneration

Info

Publication number
ZA94887B
ZA94887B ZA94887A ZA94887A ZA94887B ZA 94887 B ZA94887 B ZA 94887B ZA 94887 A ZA94887 A ZA 94887A ZA 94887 A ZA94887 A ZA 94887A ZA 94887 B ZA94887 B ZA 94887B
Authority
ZA
South Africa
Prior art keywords
myelinassociated
neurotrophin
combination
nervous system
directed toward
Prior art date
Application number
ZA94887A
Other languages
English (en)
Inventor
Martin E Schwab
Lisa Schnell
Original Assignee
Zuerich Erziehungsdirektion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zuerich Erziehungsdirektion filed Critical Zuerich Erziehungsdirektion
Publication of ZA94887B publication Critical patent/ZA94887B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA94887A 1993-02-11 1994-02-09 A combination of neurotrophin and antibody directed toward myelinassociated neurite growth inhibitory protein promotes central nervous system regeneration ZA94887B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1635493A 1993-02-11 1993-02-11

Publications (1)

Publication Number Publication Date
ZA94887B true ZA94887B (en) 1994-08-23

Family

ID=21776697

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA94887A ZA94887B (en) 1993-02-11 1994-02-09 A combination of neurotrophin and antibody directed toward myelinassociated neurite growth inhibitory protein promotes central nervous system regeneration

Country Status (7)

Country Link
EP (1) EP0634939A1 (fr)
JP (1) JPH07509002A (fr)
AU (1) AU5891394A (fr)
CA (1) CA2117889A1 (fr)
IL (1) IL108600A0 (fr)
WO (1) WO1994017831A1 (fr)
ZA (1) ZA94887B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576441B1 (en) 1995-12-06 2003-06-10 Sumitomo Pharmaceuticals Company, Limited Semaphorin Z and gene encoding the same
WO1998011216A1 (fr) 1996-09-11 1998-03-19 Sumitomo Pharmaceuticals Company, Limited Nouveau gene de semaphorine: semaphorine y
US6902730B1 (en) 1996-10-09 2005-06-07 Sumitomo Pharmaceuticals Company, Limited Semaphorin gene: Semaphorin W
CA2190418A1 (fr) * 1996-11-15 1998-05-15 Zhi-Cheng Xiao Systeme regulateur pour la croissance des neurones et des tumeurs neuronales; anticorps utilises a cette fin et applications
AU4964097A (en) 1996-11-15 1998-06-10 Sumitomo Pharmaceuticals Company, Limited Novel semaphorin genes (i)
EP0878480A1 (fr) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller Procédé pour ameliorer la régénération nerveuse
SE9901428D0 (sv) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
AU784349C (en) 2000-01-12 2006-09-28 Yale University Nogo receptor-mediated blockade of axonal growth
NZ525422A (en) 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
CA2549000A1 (fr) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Procede de traitement de troubles neurologiques
US8912144B2 (en) 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100196540B1 (ko) * 1988-11-04 1999-06-15 마틴 이. 샤브 축색성장 조절인자
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
WO1993000427A2 (fr) * 1991-06-24 1993-01-07 Erziehungsdirektion Of The Canton Zurich Facteurs regulateurs de la croissance des neurites
JP2008027291A (ja) * 2006-07-24 2008-02-07 Hitachi Ltd ストレージ装置及びデータ保護方法

Also Published As

Publication number Publication date
JPH07509002A (ja) 1995-10-05
IL108600A0 (en) 1994-05-30
CA2117889A1 (fr) 1994-08-18
EP0634939A1 (fr) 1995-01-25
WO1994017831A1 (fr) 1994-08-18
AU5891394A (en) 1994-08-29

Similar Documents

Publication Publication Date Title
GB9624256D0 (en) Watere treatment process and system
EP0766651A4 (fr) Procede et systeme de denitrification controlee
EP0785276A4 (fr) Modification d'un peptide et d'une proteine
AU1875692A (en) Exhaust treatment system and method
IL109268A0 (en) Pattern recognition method and system
AU4638393A (en) Process for hemoglobin extraction and purification
HUP9900935A3 (en) Antifungic and antibacterial peptide and process for preparation
EP0775711A4 (fr) Peptide a action inhibant l'agregation plaquettaire et procede de production de ce compose
ZA94887B (en) A combination of neurotrophin and antibody directed toward myelinassociated neurite growth inhibitory protein promotes central nervous system regeneration
HUP9900323A2 (hu) Bakteriofág endoszialidáz aktivitással rendelkező rekombináns fehérje
SG79882A1 (en) Protein having tpo activity
EP0559098A3 (en) Engine control system and method
EP0593663A4 (en) Method and assay system for neurotrophin activity
AU1996599A (en) Long-term survival and regeneration of central nervous system neurons
AU4362696A (en) Growth inhibitory peptide and methods of using same
EP0838432A4 (fr) Corps d'epuration par milieu dense et epurateur
IL109280A0 (en) Neurotrophins for treatment of depression
EP0781297A4 (fr) Derives de cytotactine stimulant la connexion neuronale et la croissance des axones et des dendrites, leurs procedes de preparation et d'utilisation
EP0833904A4 (fr) Facteur de croissance des fibroblastes 14
SG52769A1 (en) Regeneration of aromatization catalysts
EP0921803A4 (fr) Procede permettant de prevenir et de traiter une infection pestivirale et les maladies qui y sont associees
GB2301783B (en) Process and system for filtering polyamide oligomers
EP0866717A4 (fr) Proteine specifique des oligodendrocytes et procede correspondant pour le traitement de maladies
ZA963417B (en) Methods of preventing neuron degeneration and promoting neuron regeneration
PL311885A1 (en) Protein of tpo activity